GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Selling, General, & Admin. Expense

Innovent Biologics (HKSE:01801) Selling, General, & Admin. Expense : HK$4,212 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Innovent Biologics's selling, general, & admin. expense for the six months ended in Dec. 2023 was HK$2,335 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$4,212 Mil.


Innovent Biologics Selling, General, & Admin. Expense Historical Data

The historical data trend for Innovent Biologics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Selling, General, & Admin. Expense Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 1,054.68 2,107.38 4,195.21 3,826.15 4,212.11

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,490.63 2,116.63 1,809.70 1,876.71 2,335.40

Competitive Comparison of Innovent Biologics's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Innovent Biologics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovent Biologics's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Selling, General, & Admin. Expense falls into.



Innovent Biologics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$4,212 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovent Biologics  (HKSE:01801) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Innovent Biologics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovent Biologics (HKSE:01801) Business Description

Industry
Traded in Other Exchanges
Address
168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Executives
Jpmorgan Chase & Co. 2502 Approved lending agent
Yu De-chao Michael 2101 Beneficial owner
Temasek Holdings (private) Limited
Brown Brothers Harriman & Co. 2502 Approved lending agent
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Morgan Stanley 2201 Interest of corporation controlled by you
Citigroup Inc. 2201 Interest of corporation controlled by you
Shi Yi 2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Eight Roads Investments 2101 Beneficial owner
Fullerton Management Pte Ltd 2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited 2201 Interest of corporation controlled by you
Tls Beta Pte. Ltd. 2101 Beneficial owner

Innovent Biologics (HKSE:01801) Headlines

No Headlines